Blood Journal
Leading the way in experimental and clinical research in hematology

Phase II study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post polycythemia vera/essential thrombocythemia myelofibrosis

This article is only available in PDF format. Please click on the PDF button to view this article.

This is a PDF-only article. The first page of the PDF of this article appears below.

PDF extract preview